---
layout: default
title: Colchicina
parent: 僅模型預測 (L5)
nav_order: 37
evidence_level: L5
indication_count: 0
---

# Colchicina
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Colchicine (Colchicina): Drug Repurposing Evaluation — Data Insufficient for Full Analysis

## One-Sentence Summary

Colchicine (Colchicina) is a well-established pharmaceutical compound, but the current Evidence Pack contains **no populated original indications**, **no TxGNN predicted indications**, and critical data gaps in mechanism of action and safety information. A meaningful repurposing analysis cannot be completed until these gaps are remediated; this report serves as a status record and remediation roadmap.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not populated in Evidence Pack |
| Predicted New Indication | No TxGNN predictions available |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not assessable |
| Italy Market Status | ✗ Not Marketed (0 authorizations found) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Italy Market Information

No marketing authorizations were returned from the registry query. Total licenses on record: **0**.

> **Note:** The query log confirms the registry search was executed successfully (result\_status: "success") but returned 0 records. If Colchicina is known to have market presence in the target territory under an alternate product name or license holder, a targeted product-name search is recommended as a follow-up step.

---

## Safety Considerations

Please refer to the package insert for safety information.

> The registry query for the package insert returned 1 result (query\_log id: 4), but the content was not transferred to the Evidence Pack. Retrieval and parsing of this document is classified as a **Blocking** gap (DG001) and must be completed before any safety evaluation can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN predicted indications, no original indication data, and two unresolved data gaps — one Blocking and one High severity — that prevent any meaningful repurposing or safety evaluation from being conducted at this time.

**To proceed, the following is needed:**

- **\[Blocking — DG001\]** Parse the package insert PDF already retrieved from the registry (query\_log id: 4) to extract warnings and contraindications; this is the precondition for entering the S1 safety screening stage
- **\[High — DG002\]** Query the DrugBank record already identified (query\_log id: 3, result\_count: 1) to populate the mechanism of action (MOA) field and original indications
- **\[Required\]** Re-run the TxGNN prediction pipeline with Colchicina as input to generate candidate repurposing indications; without predictions, no repurposing analysis can be initiated
- **\[Advisory\]** Verify Italy/AIFA marketing authorization status via a product-name search (e.g., "Colchicina Houde" or other known brand names), as the current 0-license result may reflect a query scope limitation rather than true market absence
- **\[Advisory\]** Confirm DrugBank ID and map to standardized INN to ensure consistent cross-source identification in future pipeline runs
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

